ASTRAZENECA

AstraZeneca PLC said its drug Fasenra failed to meet the main goal of a late-stage trial aimed at treating chronic obstructive pulmonary disease, or COPD, marking another recent setback for the drugmaker's development pipeline.

AstraZeneca PLC said its experimental drug for a rare disease failed to meet the main goal of a late-stage study, a setback for its growing rare disease business.

AstraZeneca PLC said its experimental drug baxdrostat succeeded in a late-stage trial for treating patients with hard-to-control high blood pressure, a common condition that has seen little therapeutic innovation in decades.